Join Growin Stock Community!

Revolution medicines, inc. warrantRVMDW.US Overview

US StockHealthcare
(No presentation for RVMDW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RVMDW AI Insights

RVMDW Overall Performance

RVMDW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RVMDW Recent Performance

-12.04%

Revolution medicines, inc. warrant

0.05%

Avg of Sector

-0.31%

S&P500

RVMDW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RVMDW Key Information

RVMDW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RVMDW Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Price of RVMDW

RVMDW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RVMDW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.85
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
57.88%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.85
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
57.88%

  • When is RVMDW's latest earnings report released?

    The most recent financial report for Revolution medicines, inc. warrant (RVMDW) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RVMDW's short-term business performance and financial health. For the latest updates on RVMDW's earnings releases, visit this page regularly.

  • How much debt does RVMDW have?

    As of the end of the reporting period, Revolution medicines, inc. warrant (RVMDW) had total debt of 158.7M, with a debt ratio of 0.07. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does RVMDW have?

    At the end of the period, Revolution medicines, inc. warrant (RVMDW) held Total Cash and Cash Equivalents of 383.75M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is RVMDW's EPS continuing to grow?

    According to the past four quarterly reports, Revolution medicines, inc. warrant (RVMDW)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.9. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RVMDW?

    Revolution medicines, inc. warrant (RVMDW)'s Free Cash Flow (FCF) for the period is -276.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 97.95% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of RVMDW?

    The latest valuation data shows Revolution medicines, inc. warrant (RVMDW) has a Price-To-Earnings (PE) ratio of -10.38 and a Price/Earnings-To-Growth (PEG) ratio of -0.58. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.